Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Go back to Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases
(NASDAQ: CRDL) Delayed: 1.01 --0 (-0%)
Previous Close $1.01    52 Week High
Open $1.00    52 Week Low
Day High $1.02    P/E N/A 
Day Low $0.98    EPS
Volume 253,734